ISCO.OB received the statutory approvals required to forward with the next phase of its stem cell banking program.
- An independent Stem Cell Research Oversight (SCRO) committee approved ISCO’s program to obtain human oocytes (eggs) in California;
- ISCO’s study is designed to produce new clinical-grade human parthenogenetic stem cell lines that can be immune matched to millions of individuals for use.
The Bottom Line: This approval in combination with the earlier Institutional Review Board (IRB) clearance with regard to medical safety opens the way for ISCO’s stem cell banking program to begin registering clinical investigators. Currently ISCO has a collection of ten hpSC lines that are shared with collaborators and used for research purposes. Although these 10 stem cell lines conform to all relevant US standards, they were derived outside the US. New cell lines created under this study will be ISCO’s 1st hpSC to be produced in the US.